Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Terutroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R known ✓ | P21731 | 11/20 | 0.84 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Terutroban SCHEMBL29378918 | 0.91 | TBXA2R (1.00) | TBXA2RTBXAS1HDAC8 | |
| Terutroban SCHEMBL43629 | 0.91 | TBXA2R (1.00) | TBXA2RTBXAS1HDAC8 | |
| Terutroban SCHEMBL1896773 | 0.91 | TBXA2R (1.00) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9252158 | 0.90 | TBXA2R (0.82) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9015417 | 0.86 | TBXA2R (0.76) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9247892 | 0.82 | TBXA2R (0.82) | TBXA2RTBXAS1 | |
| SCHEMBL12675846 | 0.82 | TBXA2R (0.82) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9246542 | 0.80 | TBXA2R (0.79) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9015506 | 0.80 | TBXA2R (0.79) | TBXA2RTBXAS1HDAC8 | |
| SCHEMBL9015468 | 0.80 | TBXA2R (0.70) | TBXA2RTBXAS1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | claimed |
| US-20240180904-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-06 | — | — | US | claimed |
| US-12263164-B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | ACERTA PHARMA B.V. (NL) | 2025-04-01 | — | — | US | disclosed |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | disclosed |
| US-20240180904-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-06 | — | — | US | disclosed |
| US-11771696-B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | ACERTA PHARMA B.V. (NL) | 2023-10-03 | — | — | US | disclosed |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | ACERTA PHARMA B.V. (NL) | 2023-05-23 | — | — | US | disclosed |
| EP-3179992-B1 | THERAPEUTIC COMBINATIONS OF A BTK INHIBITOR, A PD-1 INHIBITOR AND/OR A PD-L1 INHIBITOR | ACERTA PHARMA BV (NL) | 2022-05-11 | — | — | EP | disclosed |
| US-20220088013-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | ACERTA PHARMA B.V. (NL) | 2022-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220088013-A1 | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a BCL-2 Inhibitor | BTK, JAK2, BCL9 | TBXA2R 2532/4885TBXAS1 2290/4885HDAC8 1620/4885 |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | BTK, LYN, SYK | TBXA2R 2047/4885TBXAS1 1727/4885HDAC8 1331/4885 |
| US-20240180904-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | BTK, LYN, SYK | TBXA2R 1176/4885TBXAS1 2097/4885HDAC8 2448/4885 |
| US-11654143-B2 | Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor, a JAK-2 inhibitor, and/or a BCL-2 inhibitor | BTK, JAK2, BCL9 | TBXA2R 2532/4885TBXAS1 2290/4885HDAC8 1620/4885 |
| US-12263164-B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | BTK, LYN, SYK | TBXA2R 1176/4885TBXAS1 2097/4885HDAC8 2448/4885 |
| US-11771696-B2 | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor | BTK, LYN, SYK | TBXA2R 1176/4885TBXAS1 2097/4885HDAC8 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.